Evotec SE(EVO)Earnings, Financials & Key RatiosEvotec SE (EVO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to achieve operational self-sufficiency is underscored by a -35.4% operating margin in 2026Q1, indicating significant risk to capital preservation.
Evotec SE (EVO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Evotec SE (EVO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.48vs $0.15-217.9% | $217Mvs $206M+5.0% |
| Q2 2026 | Apr 8, 2026 | $0.05vs $0.21-74.0% | $348Mvs $329M+5.7% |
| Q4 2025 | Nov 5, 2025 | $0.14vs $0.14-1.4% | $192Mvs $240M-20.0% |
| Q3 2025 | Aug 13, 2025 | $0.14vs $0.18+19.9% | $202Mvs $192M+5.1% |
Recent stock market news and headlines for Evotec SE (EVO)
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics PR Newswire S
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform Enables deployment of continuous manufacturing platform in partner-owned facilities to support higher productivity and flexibility compared with fed-batch technology biologics manufacturing Modular manufacturing infrastructure, equipment and proprietary technology enable rapid and cost-efficient increase in capacity for biologics manufacturing SEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion.
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU).The Phas.
Key metrics vs top competitors for Evotec SE (EVO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.85 | $1.01B | -8.91 | -4.98% | -13.13% | -11.26% | — | |
| $208.23 | $35.34B | 26.56 | 5.87% | 8.33% | 22.11% | — | |
| $228.68 | $11.01B | -78.58 | -0.85% | -4.59% | -5.66% | — | |
| $546.29 | $15.6B | 35.75 | 19.97% | 17.19% | 120.89% | — | |
| $130.60 | $17.89B | 5856.50 | 2.72% | 3.46% | 2.79% | — | |
| $3.84 | $1.72B | -2.67 | 26.92% | -844.46% | -54.32% | — |
Evotec SE (EVO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EVO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Evotec SE (EVO) stock FAQ — growth, dividends, profitability & financials explained
Evotec SE (EVO) reported $745.2M in revenue for fiscal year 2025. This represents a 20757% increase from $3.6M in 2003.
Evotec SE (EVO) saw revenue decline by 5.0% over the past year.
Evotec SE (EVO) reported a net loss of $196.0M for fiscal year 2025.
Evotec SE (EVO) has a return on equity (ROE) of -11.3%. Negative ROE indicates the company is unprofitable.
Evotec SE (EVO) had negative free cash flow of $44.9M in fiscal year 2025, likely due to heavy capital investments.
